More than 12,000 people are diagnosed with primary brain tumours every year in the UK, according to the UK National Health Service (NHS). Image Credit: Alina.Alina / Shutterstock.

Netherlands-based myTomorrows and UK-based charity brainstrust have partnered to improve patient and clinician access and awareness of clinical trials for brain tumours.

As part of the partnership, myTomorrows will provide patient navigators who will help patients and healthcare professionals navigate brainstrust’s network and obtain information regarding clinical trials in the space. This allows for increased patient recruitment, it also aligns with the UK Government’s plans to include general practitioners (GPs) in the trial process.

More than 12,000 people are diagnosed with primary brain tumours every year in the UK, according to the UK National Health Service (NHS).

As per the GlobalData Pharmaceutical Intelligence Centre, there are over 700 clinical trials for brain tumour indication, with more than 70% of these therapeutic candidates currently in early clinical development.

GlobalData is the parent company of Clinical Trials Arena.

See Also:

“Collaborating with leading patient advocacy organisations like brainstrust allows myTomorrows to extend our reach to patients affected by numerous conditions,” said Michel van Harten, CEO of myTomorrows.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This partnership forms part of our overall mission to raise patients’ and physicians’ awareness of different treatment options while enabling pharmaceutical companies to expand access throughout the drug development cycle.”

Last month, myTomorrows partnered with the US-based charity, the ALS Association, to improve patient accessibility to clinical trials for amyotrophic lateral sclerosis (ALS) therapies.

Clinical trials allow patients to access new treatments without incurring high costs. A diverse patient group in clinical trials allows sponsors to compile a more robust data set with a more representative population. Furthermore, the lack of recruitment is one of the main reasons for trial termination, with more than 80% of trials failing to enrol participants on time.

Multiple companies have invested in developing technologies to combat the lack of patient recruitment. In October 2023, Elligo Health Research and Avallano launched myTrialsConnect, an AI-powered clinical trial recruitment and engagement platform. Patients receive alerts on myTrialsConnect if they become eligible for a particular clinical trial based on an automated review of their medical records and chatbot-based surveys.

A 2023 British Medical Journal (BMJ) published study found that scanning electronic health records (HER) can expand the patient pool and boost recruitment.

During the 12 months, the researchers were able to contact 22,741 patients identified by EHR, including 2,716 patients via clinician-referrals and self-referrals, as well as 20,025 via electronic searches. This represented a 637% increase over patients who were contactable via traditional means.